"Anticholesteremic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances used to lower plasma CHOLESTEROL levels.
| Descriptor ID |
D000924
|
| MeSH Number(s) |
D27.505.519.186.071.202 D27.505.954.557.500.202
|
| Concept/Terms |
Anticholesteremic Agents- Anticholesteremic Agents
- Agents, Anticholesteremic
- Inhibitors, Cholesterol
- Cholesterol Inhibitors
- Anticholesteremic Drugs
- Drugs, Anticholesteremic
- Anticholesteremics
|
Below are MeSH descriptors whose meaning is more general than "Anticholesteremic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anticholesteremic Agents".
This graph shows the total number of publications written about "Anticholesteremic Agents" by people in this website by year, and whether "Anticholesteremic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 3 | 2 | 5 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2019 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anticholesteremic Agents" by people in Profiles.
-
Jia X, Ramsey DJ, Rifai MA, Ahmed ST, Akeroyd JM, Dixon DL, Gluckman TJ, Nambi V, Ballantyne CM, Petersen LA, Stone NJ, Virani SS. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
-
Ramsaran E, Preusse P, Sundaresan D, DiMario S, Patel J, Harrison D, Munsell M, Menzin J. Adherence to Blood Cholesterol Treatment Guidelines Among Physicians Managing Patients With Atherosclerotic Cardiovascular Disease. Am J Cardiol. 2019 07 15; 124(2):169-175.
-
Cannon CP, Sanchez RJ, Klimchak AC, Khan I, Sasiela WJ, Reynolds MR, Rosenson RS. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease. Am J Cardiol. 2019 04 15; 123(8):1202-1207.
-
Cannon CP, Khan I, Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2017 09 01; 2(9):959-966.
-
Fei Y, Guyatt GH, Alexander PE, El Dib R, Siemieniuk RAC, Vandvik PO, Nunnally ME, Gomaa H, Morgan RL, Agarwal A, Zhang Y, Bhatnagar N, Spencer FA. Addition of Ezetimibe to statins for patients at high cardiovascular risk: Systematic review of patient-important outcomes. J Eval Clin Pract. 2018 02; 24(1):222-231.
-
Khvorova A. Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. N Engl J Med. 2017 Jan 05; 376(1):4-7.
-
Turner PL, Barry KA. Alirocumab (Praluent) for Treatment of Hyperlipidemia. Am Fam Physician. 2016 Aug 15; 94(4):310-1.
-
Panza GA, Taylor BA, Thompson PD, Erhard L, Capizzi JA, Grimaldi AS, Cole SM, Chipkin S, Keadle J, White CM, Pescatello LS. The Effect of Atorvastatin on Habitual Physical Activity among Healthy Adults. Med Sci Sports Exerc. 2016 Jan; 48(1):1-6.
-
Jarcho JA, Keaney JF. Proof That Lower Is Better--LDL Cholesterol and IMPROVE-IT. N Engl J Med. 2015 Jun 18; 372(25):2448-50.
-
Shrank WH, Sussman A, Brennan TA. The role of retail pharmacies in CVD prevention after the release of the ATP IV guidelines. Am J Manag Care. 2014 Nov 01; 20(11):e487-9.